EMA Application withdrawn: Aliqopa (copanlisib dihydrochloride) — Bayer AG

View source ↗

Summary

The EMA has withdrawn the application for Aliqopa (copanlisib dihydrochloride) by Bayer AG for its use in lymphoma subtypes including marginal zone lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Aliqopa (copanlisib)

Snippet

Status: Application withdrawn. Therapeutic area: Lymphoma, B-Cell, Marginal Zone. MAH: Bayer AG. Orphan medicine